Testing to treatment of BRAF-mutant metastatic NSCLC

Testing to treatment of BRAF-mutant metastatic NSCLC

Testing to treatment of BRAF-mutant metastatic NSCLC

In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies and first- and second-line treatment options for these patients.

The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients. Various treatments are considered, along with which decision criteria come into play when selecting a particular treatment.

The experts also discuss how to treat patients who have co-mutations detected during testing.

This is an informative podcast that culminates in some interesting key messages from two well-recognised Experts in the field of NSCLC.

Key clinical takeaways:

  • Test all patients irrespective of histology and smoking history
  • Test upfront so that more efficacious agents can be used earlier in the patient journey
  • Next-generation sequencing is the gold-standard for testing wherever possible to ensure various targetable alterations are not missed
  • There are effective BRAF + MEK inhibitor combination treatments available to treat our BRAFv600E-mutant metastatic NSCLC patients which have manageable safety profiles

Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/UZPBUAFOwcY

Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/lung-connect/programmes/testing-treatment-braf-mutant-metastatic-nsclc/

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/lungconnect/

X: https://x.com/lung_connect

This content is intended for healthcare professionals outside of the UK & ROI only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.

This podcast is developed by https://cor2ed.com/

Published November 2024

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(92)

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer    Key clinical takeaways:   Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multi...

12 Mar 23min

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binar...

17 Des 202525min

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressi...

7 Nov 202527min

Exploring the role of targeted radiopharmaceutical treatment in NETs

Exploring the role of targeted radiopharmaceutical treatment in NETs

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing,...

30 Sep 202521min

Tackling mPDAC: chemotherapy strategies that matter

Tackling mPDAC: chemotherapy strategies that matter

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall surv...

19 Mai 202521min

Understanding Rare NSCLC Mutations: Insights, access and support

Understanding Rare NSCLC Mutations: Insights, access and support

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE)...

14 Mai 202520min

The HER2 diagnostic and treatment landscape in NSCLC

The HER2 diagnostic and treatment landscape in NSCLC

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC  This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology B...

28 Apr 202518min

The HER2 Diagnostic and Treatment Landscape in NSCLC

The HER2 Diagnostic and Treatment Landscape in NSCLC

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives  This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC,...

15 Apr 202521min

Populært innen Fakta

fastlegen
dine-penger-pengeradet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
foreldreradet
treningspodden
jakt-og-fiskepodden
rss-strid-de-norske-borgerkrigene
rss-kunsten-a-leve
mikkels-paskenotter
rss-kull
sinnsyn
smart-forklart
rss-sarbar-med-lotte-erik
hverdagspsyken
rss-bisarr-historie
gravid-uke-for-uke
rss-var-forste-kaffe
level-up-med-anniken-binz
rss-impressions-2
rss-det-virker-en-podkast-om-spesialpedagogikk